Monday, September 28, 2026
BTC $83,079 ▼ 0.46%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
ADA$0.246down−0.62%ETH$2,673down−0.55%LINK$15.34down−0.70%SOL$117.96down−0.73%BTC$83,079down−0.46%XRP$1.49down−0.61%S&P 5007,684down−0.77%Nasdaq26,820down−0.92%Dow51,482down−0.67%RUT2,818down−0.69%TNX5.24%up+1.08%TYX5.56%up+1.04%FVX5.07%up+1.22%IRX4.06%down−0.32%VIX16.07up+8.07%GOLD$4,150.70down−0.42%SILVER$61.04down−1.10%OIL$93.36up+0.82%DXY101.23up+0.03%NVDA$228.86up+1.68%AAPL$338.40down−0.78%TSLA$357.45down−3.94%META$715.62down−4.79%MSFT$509.22down−1.35%AMZN$246.15down−1.41%GOOGL$342.75down−0.34%Fear & Greed73 — GreedADA$0.246down−0.62%ETH$2,673down−0.55%LINK$15.34down−0.70%SOL$117.96down−0.73%BTC$83,079down−0.46%XRP$1.49down−0.61%S&P 5007,684down−0.77%Nasdaq26,820down−0.92%Dow51,482down−0.67%RUT2,818down−0.69%TNX5.24%up+1.08%TYX5.56%up+1.04%FVX5.07%up+1.22%IRX4.06%down−0.32%VIX16.07up+8.07%GOLD$4,150.70down−0.42%SILVER$61.04down−1.10%OIL$93.36up+0.82%DXY101.23up+0.03%NVDA$228.86up+1.68%AAPL$338.40down−0.78%TSLA$357.45down−3.94%META$715.62down−4.79%MSFT$509.22down−1.35%AMZN$246.15down−1.41%GOOGL$342.75down−0.34%Fear & Greed73 — Greed
Tag

cancer vaccine

2 articles

Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk
U.S. Equities37d ago
Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk
Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Research & Analysis40d ago
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.